ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 977,97
-0,01%
Dow Jones
38 111,48
-0,86%
DAX
18 468,77
-0,24%
Brent Oil
81,775
-0,21%
Bitcoin
68 145,51
-0,31%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Perspective Therapeutics Inc (CATX)

  7. Perspective Therapeutics Inc (CATX) Actualités

CATX

Perspective Therapeutics (CATX)

Perspective Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:CATX
DateHeureSourceTitreSymboleSociété
24/05/202414h01GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsAMEX:CATXPerspective Therapeutics Inc
20/05/202413h00GlobeNewswire Inc.Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024AMEX:CATXPerspective Therapeutics Inc
15/05/202413h00GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsAMEX:CATXPerspective Therapeutics Inc
03/05/202413h00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming May Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
02/05/202413h00GlobeNewswire Inc.Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
30/04/202413h00GlobeNewswire Inc.Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsAMEX:CATXPerspective Therapeutics Inc
08/04/202414h00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming April Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
28/03/202412h30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaAMEX:CATXPerspective Therapeutics Inc
11/03/202413h00GlobeNewswire Inc.Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024AMEX:CATXPerspective Therapeutics Inc
05/03/202414h00GlobeNewswire Inc.Perspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityAMEX:CATXPerspective Therapeutics Inc
04/03/202415h45GlobeNewswire Inc.Perspective Therapeutics Announces $87.4 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
26/02/202414h00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
12/02/202414h00GlobeNewswire Inc.Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceAMEX:CATXPerspective Therapeutics Inc
22/01/202422h05GlobeNewswire Inc.Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
18/01/202413h00GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
17/01/202422h05GlobeNewswire Inc.Perspective Therapeutics Announces Proposed Public OfferingAMEX:CATXPerspective Therapeutics Inc
17/01/202414h00GlobeNewswire Inc.Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01AMEX:CATXPerspective Therapeutics Inc
09/01/202422h10AllPennyStocks.comAnother Healthcare Stock Stealing The ShowAMEX:CATXPerspective Therapeutics Inc
09/01/202414h00GlobeNewswire Inc.Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing CapabilityAMEX:CATXPerspective Therapeutics Inc
09/01/202414h00GlobeNewswire Inc.Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective TherapeuticsAMEX:CATXPerspective Therapeutics Inc
05/01/202414h00GlobeNewswire Inc.Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer TreatmentAMEX:CATXPerspective Therapeutics Inc
02/01/202414h00GlobeNewswire Inc.Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceAMEX:CATXPerspective Therapeutics Inc
12/12/202314h00GlobeNewswire Inc.Perspective Therapeutics Divests Brachytherapy BusinessAMEX:CATXPerspective Therapeutics Inc
07/12/202314h00GlobeNewswire Inc.Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine TumorsAMEX:CATXPerspective Therapeutics Inc
14/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
14/06/202322h42Edgar (US Regulatory)Specialized Disclosure Report (sd)AMEX:CATXPerspective Therapeutics Inc
15/05/202323h23Edgar (US Regulatory)Quarterly Report (10-q)AMEX:CATXPerspective Therapeutics Inc
15/05/202323h16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:CATXPerspective Therapeutics Inc
01/05/202323h04Edgar (US Regulatory)Annual Transition Report (10-kt)AMEX:CATXPerspective Therapeutics Inc
 Showing the most relevant articles for your search:AMEX:CATX

Dernières Valeurs Consultées

TG
A4W
Arise AB
LSE
88KI
Segro 37
LSE
80GW
Investec Bnk 26
EU
MTB
Amundi Euro Government B...
TSXV
APC
Advanced Proteome Therap...
HITB
FRECBTC
Freyr Coin
TSXV
MILL
Millbank Mining
ASX
OXTN
Orexplore Technologies
NASDAQ
AGNCB
AGNC Investment
LSE
62AR
Int.fin. 27
COIN
SFUSDETH
StableFund USD
TG
1KQ
Atlas Pearls
LSE
68TQ
Sthn.pac.fin4es
TG
42FB
AIML Innovations
COIN
BCDTETH
NYSE
FMDE
Fidelity Covingt
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés